Mangalam Drugs tells NSE it defaulted on loans from two banks
Mangalam Drugs and Organics said in an NSE filing that it has defaulted for over 30 days on cash credit loans from Bank of Baroda and Bank of Maharashtra.
Key points
- Mangalam Drugs and Organics told the National Stock Exchange on 16 November 2026 that it has defaulted on loans from two banks.
- The company reported Rs 951.19 lakh overdue to Bank of Maharashtra and Rs 606.08 lakh to Bank of Baroda as on 15 November 2026.
- The filing gives no reason for the default and says the company is arranging to pay the overdue amounts as soon as possible.
Mangalam Drugs and Organics Limited said in a filing with the National Stock Exchange on 16 November 2026 that it has defaulted on its loan obligations to Bank of Baroda and Bank of Maharashtra for more than 30 days. The company reported Rs 951.19 lakh overdue to Bank of Maharashtra and Rs 606.08 lakh overdue to Bank of Baroda as on 15 November 2026.
What Happened
The company made the disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. That rule requires a listed company to tell the exchange when it fails to pay interest or principal in full on the date a debt falls due. For cash credit accounts, which work like a revolving limit, a company is treated as being in default if the balance stays above the sanctioned limit or drawing power, whichever is lower, for more than 30 days.
The filing lists two cash credit accounts. For the account with Bank of Maharashtra, the company reported Rs 951.19 lakh overdue as on 15 November 2026, with the default starting on 17 October 2025. For the account with Bank of Baroda, it reported Rs 606.08 lakh overdue as on the same date, with the default starting on 20 October 2025.
The company described the filing as a subsequent intimation. A covering letter from its chief financial officer says it follows the company's earlier letter dated 16 February 2026. The filing does not give a reason for the default. It says only that the company is making arrangements to pay the overdue amount as soon as possible. It does not say when payment is expected.
What It Means
This is the company's own disclosure of overdue bank dues. It is not a finding of wrongdoing by any regulator, court or lender, and the filing does not say that any bank has taken action against the company.
For shareholders and others who deal with the company, the filing shows that the overdue amounts to two lenders were still unpaid on 15 November 2026. The filing does not say whether the dues have been restructured, whether the banks have classified the accounts in any particular way, or when the overdue amounts will be cleared. Readers should treat those points as unknown until the company or the lenders disclose more.
The full filing is available on the National Stock Exchange website under the company's announcements. Complaints against listed companies can be lodged at https://scores.sebi.gov.in.
Oquilia Data: Mangalam Drugs And Organics Ltd. (NSE: MANGALAM)
| Close, 13 Nov 2026 | Rs 29.23 (+0.17% on the day) |
|---|---|
| Return 1M / 3M / 6M / YTD / 1Y | −8.80% / +5.18% / −4.57% / +6.25% / −52.82% |
| Against Nifty 50, 1M / 3M / YTD | −19.46 / +2.11 / +10.02 points |
| 52-week closing high / low | Rs 62.30 (14 Nov 2025) / Rs 23.78 (26 Dec 2025) |
| Turnover, 20-session average | Rs 0.05 cr; 75.5% delivered; latest volume 0.4x |
Closes adjusted for splits and bonuses; returns exclude dividends. Facts from NSE's files, not investment advice.
Source: Company filing on NSE
Sources & Citations
- Company filing on NSE — National Stock Exchange of India